|
| |
A convenient
digital info kit |
| Press Kit >> Snapshot (2006-07) |
|
| |
| BASED ON U.S. GAAP FINANCIALS |
|
| |
|
CONSOLIDATED REVENUES grew by 168 per cent, from Rs. 24,267 million in 2005–06 to Rs. 65,095 million, or U.S.$. 1.51 billion.
OPERATING INCOME Increased almost eight-fold from Rs. 1,442 million in 2005–06 to Rs. 11,224 million in 2006–07. |
PROFIT BEFORE TAX AND MINORITY INTERESTS Grew by more than 450 per cent from Rs. 1,888 million in 2005–06 to Rs. 10,500 million, or U.S.$. 243.6 million.
PROFIT AFTER TAX increased almost five-fold from Rs. 1,629 million in 2005–06 to Rs. 9,327 million, or U.S.$. 216 million.
|
FULLY DILUTED EARNINGS PER SHARE rose from Rs. 10.62 in 2005–06 to Rs. 58.56 in 2006–07.
R&D EXPENSES grew by 14 per cent to Rs. 2,463 million for 2006–07. As a share of total revenue, R&D expenditure was at 4 per cent in 2006–07, compared to 9 per cent in 2005 -06
|
| REVENUES FROM DIFFERENT BUSINESSES |
REVENUE FROM API Increased by 44 per cent from Rs. 8,238 million in 2005–06 to Rs. 11,827 million in 2006–07. International revenues accounted for 82 per cent of API revenues.
FORMULATIONS REVENUES increased by 24 per cent from Rs. 9,926 million in 2005–06 to Rs. 12,319 million in 2006–07.
- Revenues in India grew by 16 per cent to Rs. 6,415 million in 2006–07.
- Revenue from international markets increased by 34 per cent from Rs. 4,400 million in 2005–06 to Rs. 5,904 million in 2006–07.
REVENUES FROM GENERICS increased from Rs.4,056 million in 2005–06 to Rs.33,224million in 2006–07.
- North American Generics revenue increased from Rs. 1,631 million in 2005–06 to Rs. 23,617 million in 2006–07, due to authorized generics and new product launches.
- Simvastatin and finasteride, launched as authorized generic versions of Zocor® and Proscar® respectively (under agreement with Merck), contributed Rs. 15,813 million.
- New products, other than authorized generics, launched during the year contributed Rs. 5,657 million to revenue. The most prominent launches were ondansetron and fexofenadine. Ondansetron, the generic version of Zofran®, was launched in the last week of December 2006 with 180-day marketing exclusivity, and contributed Rs. 2,890 million. Dr. Reddy’s has already acquired 62 per cent market share. Fexofenadine, the generic version of Allegra®, contributed Rs. 2,429 million.
CPS REVENUE increased from Rs. 1,327 million in 2005–06 to Rs. 6,600 million in 2006–07. |
| CONSOLIDATED REVENUES |
PROFIT AFTER TAX |
REVENUE MIX |
 |
 |
 |
|
| GEOGRAPHIC MIX OF APIs |
OF BRANDED FORMULATIONS |
OF GENERICS |
|
|
| ANDAs, DMFs, PRODUCT REGISTRATION AND NCEs |
|
ANDAs IN U.S.
In 2006–07, the Company filed 33 ANDAs in the U.S., including 7 Para IV filings. With the current year filings, Dr. Reddy’s has joined the elite club of 100+ ANDA filers.
HIGHEST NUMBER OF APPROVALS FOR ANDA FILINGS
2006–07 also saw the highest number of approvals for the Company’s ANDA filings: 14 final approvals and 5 tentative approvals. As of March 31, 2007, the Company’s U.S. Generic pipeline comprises 69 ANDAs pending with the U.S. FDA, including 12 tentative approvals and 29 Para IVs.
DMFs
Regarding APIs, the Company filed 56 DMFs globally in 2006–07. Of these, 23 were filed in U.S., 11 in Canada, 9 in Europe and 13 in other countries. With these filings, Dr. Reddy’s has a total 104 U.S. DMFs up to date. As on March 31, 2007, the Company has made cumulative filings of 227 DMFs.
FORMULATIONS
In Formulations, a total of 479 dossiers have been filed for product registrations in various countries.
NEW CHEMICAL ENTITIES (NCEs)
As on March 31, 2007, Dr. Reddy’s had seven molecules or New Chemical Entities (NCEs), of which five are in clinical development and two are in the pre-clinical stages.
|
|
| ANDAs IN U.S. |
DMFs |
FORMULATIONS |
|
|
|
|
|
AGREEMENT WITH CLIN TEC INTERNATIONAL for the joint development of its anti-cancer compound, DRF 1042.
|
AGREEMENT WITH TORRENT PHARMACEUTICALS for exclusive commercialization of two of Torrent’s brands in Russia, viz. Listril (Lisinopril) and Listril Plus (Lisinopril HCTZ), both of which are cardiovascular drugs used in the treatment of high blood pressure.
|
TEAMS UP with UNIVERSITY OF AUCKLAND for the world’s first Polypill trial. |
|
| |
|
|
